Clinical Trials Logo

Ataxia, Cerebellar clinical trials

View clinical trials related to Ataxia, Cerebellar.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03901638 Terminated - Clinical trials for Multiple System Atrophy

Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy

Start date: April 2, 2019
Phase: Phase 3
Study type: Interventional

Multiple system atrophy (MSA) is a fetal, rare neurodegenerative disease presenting with parksinonism, autonomic dysfunction, and cerebellar ataxia. Numerous anti-parkinsonism agents have been developed. However, no medication has yet been proven effective for the symptomatic or even causative treatment in cerebellar ataxia. To our knowledge, cerebellar N-methyl-D- aspartic acid (NMDA) receptors play a special role in the modulation of motor learning and coordination. Tllsh2910, a NMDA modulator, has been found to attenuate the ataxic gait in the mouse model. Here, we designed a large-scale double-blind randomized controlled, cross-over phase III trial to investigate the efficacy of Tllsh2910 in neurodegenerative ataxic patients and the association of gut microbiota change.